The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 13, 2022
Filed:
Mar. 22, 2017
Applicant:
Immunocore Limited, Abingdon, GB;
Inventors:
Tara Mahon, Abingdon, GB;
Yi Li, Abingdon, GB;
Assignee:
Immunocore Limited, Abingdon, GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); C07K 16/28 (2006.01); A61K 47/64 (2017.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); C07K 16/2809 (2013.01); A61K 38/00 (2013.01); A61K 47/6425 (2017.08); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01);
Abstract
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17. Said TCRs comprise non-natural mutations within the alpha and/or beta variable domains relative to a native HIV TCR. The TCRs of the invention possess unexpectedly high affinity, specificity and sensitivity for a complex of SEQ ID NO: 1 and HLA-A*02, and drive a particularly potent T cell response. Such TCRs are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.